Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ENOV 
Enovis Corp (ENOV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: ENOV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $52.2
1 Year Target Price $52.2
| 7 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -39.37% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.81B USD | Price to earnings Ratio - | 1Y Target Price 52.2 |
Price to earnings Ratio - | 1Y Target Price 52.2 | ||
Volume (30-day avg) 11 | Beta 1.79 | 52 Weeks Range 25.47 - 49.83 | Updated Date 09/12/2025 |
52 Weeks Range 25.47 - 49.83 | Updated Date 09/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -14.95 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -37.8% | Operating Margin (TTM) 2.41% |
Management Effectiveness
Return on Assets (TTM) 0.89% | Return on Equity (TTM) -28.25% |
Valuation
Trailing PE - | Forward PE 8.94 | Enterprise Value 3225804578 | Price to Sales(TTM) 0.82 |
Enterprise Value 3225804578 | Price to Sales(TTM) 0.82 | ||
Enterprise Value to Revenue 1.47 | Enterprise Value to EBITDA 22.42 | Shares Outstanding 57159800 | Shares Floating 56426443 |
Shares Outstanding 57159800 | Shares Floating 56426443 | ||
Percent Insiders 1.56 | Percent Institutions 121.34 |
Upturn AI SWOT
Enovis Corp
Company Overview
History and Background
Enovis Corp, formerly Colfax Corporation and DJO Global, focuses on medical technology. DJO Global was founded in 1978. The company has grown through acquisitions and organic growth, evolving into a significant player in the orthopedic and medical device market.
Core Business Areas
- Prevention & Recovery: This segment focuses on bracing and supports, rehabilitation and pain management products, and vascular therapy systems.
- Reconstructive: This segment focuses on large joint implants like hips and knees, as well as shoulder, elbow, foot, and ankle reconstruction and sports medicine products.
Leadership and Structure
Matt Trerotola serves as Chief Executive Officer. The company has a typical corporate structure with a board of directors and various executive leadership positions overseeing different functional areas and business segments.
Top Products and Market Share
Key Offerings
- MotionMD: MotionMD is a patient-direct fulfillment program designed to help orthopedic practices dispense DME (durable medical equipment). Competitors include Breg and Ossur. Market share for Enovis in DME bracing is estimated at 20-25% overall.
- DJO Surgical: DJO Surgical offers a range of hip and knee implants, as well as sports medicine and reconstruction products. Competitors include Stryker (SYK), Zimmer Biomet (ZBH), and Smith & Nephew (SNN). Market share varies by product line, with significant competition in the large joint reconstruction market.
Market Dynamics
Industry Overview
The orthopedic device market is driven by an aging population, increasing rates of obesity, and advancements in surgical techniques and materials. The market is competitive and highly regulated.
Positioning
Enovis is a leading player in the orthopedic and medical device market with a broad portfolio of products and services. It competes on innovation, product quality, and customer service.
Total Addressable Market (TAM)
The global orthopedic device market is estimated to be over $50 billion. Enovis is positioned to capture a portion of this market through its diverse product offerings and strategic acquisitions.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Broad product portfolio
- Established distribution network
- Focus on innovation
Weaknesses
- High debt levels (relative to assets)
- Exposure to reimbursement pressures
- Dependence on acquisitions for growth
- Integration challenges from acquisitions
Opportunities
- Expanding into emerging markets
- Developing new technologies
- Acquiring complementary businesses
- Increasing demand for minimally invasive procedures
Threats
- Increased competition
- Pricing pressures
- Regulatory changes
- Product liability claims
Competitors and Market Share
Key Competitors
- SYK
- ZBH
- BSX
- SNN
Competitive Landscape
Enovis competes with larger, more established players in the orthopedic device market. Its competitive advantages include its strong brand recognition, broad product portfolio, and focus on innovation. However, it faces challenges from competitors with greater financial resources and market share.
Major Acquisitions
LiteCure
- Year: 2023
- Acquisition Price (USD millions): 300
- Strategic Rationale: Expands Enovis' Recovery Sciences portfolio into laser therapy, increasing offerings for pain management and tissue healing.
Growth Trajectory and Initiatives
Historical Growth: Enovis's historical growth has been driven by a combination of organic growth and acquisitions. Recent years have seen revenue growth, but profitability has been impacted by acquisition-related expenses and restructuring costs.
Future Projections: Analyst estimates suggest continued revenue growth for Enovis, driven by its innovative product pipeline and expansion into new markets. Profitability is expected to improve as the company realizes synergies from its acquisitions.
Recent Initiatives: Recent initiatives include new product launches, strategic acquisitions, and cost-reduction programs.
Summary
Enovis shows promise with a diverse product range and strategic acquisitions, though it grapples with debt and intense competition. Revenue growth is expected but profitability improvements hinge on acquisition integration. Key strengths include brand recognition and innovation, while weaknesses involve debt levels and competitive pressure. Monitoring market dynamics and competitor actions is crucial for sustained success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and represents a general overview of Enovis Corp. It is not financial advice, and investors should conduct their own due diligence before making any investment decisions. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enovis Corp
Exchange NYSE | Headquaters Wilmington, DE, United States | ||
IPO Launch date 2008-05-08 | CEO & Director Mr. Damien McDonald | ||
Sector Healthcare | Industry Medical Devices | Full time employees 7367 | Website https://www.enovis.com |
Full time employees 7367 | Website https://www.enovis.com | ||
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company's Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Its Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. It distributes its products through independent distributors and directly under the ESAB and DJO brands. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.